Company news
Lumos Diagnostics Holdings Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Lumos Secures Two Service Agreements With Hologic
November 22, 2022
LDX signs agreement to raise $8m & announces General Meeting
November 20, 2022
Publication of Data from DISRUPT Clinical Trial in JAMA
October 19, 2022
Lumos Completes Closure of Sarasota Facility
October 2, 2022
Outcome of Appeal to FDA for FebriDx
October 2, 2022
FY22 Full Year Results Media Release
August 25, 2022
FY22 Full Year Results Investor Presentation
August 25, 2022
FY22 Annual Report
August 25, 2022
FY22 Appendix 4E
August 25, 2022
Lumos Pilot Manufacturing to Commence in Carlsbad
August 22, 2022
Lumos Withdraws from Local Manufacturing Proposal
August 8, 2022
Lumos Files Appeal To The FDA For FebriDx
August 7, 2022
Lumos To Close Sarasota Facility
August 1, 2022
Reinstatement to Official Quotation
July 11, 2022
FDA Decision for FebriDx
July 10, 2022
Voluntary Suspension
July 7, 2022
Security Class Reinstatement of Quotation LDXO
June 30, 2022
ViraDx Receives Interim Order Authorisation in Canada
June 26, 2022
Security Class Suspension from Quotation LDXO
June 23, 2022
Lumos Diagnostics Appoints Doug Ward as CEO
June 21, 2022
Lumos secures initial development services contract
June 16, 2022
Successful Completion of Institutional Entitlement Offer
June 7, 2022
Target Market Determination
June 6, 2022
Operational Update and Accelerated Entitlement Offer
June 6, 2022
Operational Review & Management Reorganisation
April 10, 2022
FebriDx Update - Brazil Market Authorisation & New Study
February 27, 2022
FY2022 Half Year Update
February 27, 2022
Lumos Diagnostics FY22 First Half Year Results
February 27, 2022
Change To Lumos Board
February 11, 2022
Victorian Government Intent for Lumos Manufacturing Hub
February 2, 2022
Over 100 Pharmacies in Liverpool UK Launch FebriDx Service
January 11, 2022
Lumos Provides ViraDx and FebriDx Regulatory Update
December 21, 2021
Lumos Receives Initial Orders for CoviDx In Canada
December 19, 2021
LDX received authorization to sell CoviDx in Canada
November 2, 2021
Monthly Activities/Appendix 4C Cash Flow Report
October 26, 2021
Update on Economic Evaluation of FebriDx
October 7, 2021
Economic Evaluation of FebriDx
October 5, 2021
U.S FDA Deprioritises EUA Application for CoviDx
September 21, 2021
FY21 Full Year Results
August 30, 2021
FY21 Full Year Results Investor Presentation
August 29, 2021
FY21 Full Year Results Media Release
August 29, 2021
FY21 Appendix 4E
August 29, 2021
Calls
Decks
The 5 newest of 35 decks. Every deck is listed under its year.
- Q1 FY27 Earnings Presentation
Earnings · 25 slides · Oct 27, 2026
- Investor Presentation (July 2026)
Investor deck · 40 slides · Jul 27, 2026
- Investor Presentation (June 2026)
Investor deck · 26 slides · Jun 11, 2026
- Q3 2026 Earnings Presentation
Earnings · 39 slides · Apr 21, 2026
- Investor Presentation (March 2026)
Investor deck · 37 slides · Mar 27, 2026